Sivia Capital Partners LLC Invests $93,000 in Haleon plc (NYSE:HLN)

Sivia Capital Partners LLC purchased a new position in Haleon plc (NYSE:HLN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,317 shares of the company’s stock, valued at approximately $93,000.

Several other large investors also recently bought and sold shares of the business. SageView Advisory Group LLC bought a new stake in Haleon in the fourth quarter worth $100,000. Wellington Management Group LLP grew its holdings in shares of Haleon by 164.6% in the fourth quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock worth $111,454,000 after purchasing an additional 8,423,475 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Haleon by 19.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,813,997 shares of the company’s stock worth $39,619,000 after purchasing an additional 772,829 shares during the last quarter. Syon Capital LLC grew its holdings in shares of Haleon by 31.4% in the fourth quarter. Syon Capital LLC now owns 67,711 shares of the company’s stock worth $557,000 after purchasing an additional 16,175 shares during the last quarter. Finally, Clear Street Markets LLC grew its holdings in shares of Haleon by 13,646.0% in the fourth quarter. Clear Street Markets LLC now owns 13,746 shares of the company’s stock worth $113,000 after purchasing an additional 13,646 shares during the last quarter. Institutional investors own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Berenberg Bank assumed coverage on shares of Haleon in a report on Wednesday, June 5th. They issued a “buy” rating on the stock. HSBC started coverage on shares of Haleon in a research report on Wednesday, April 17th. They set a “buy” rating for the company. Finally, Argus reissued a “buy” rating on shares of Haleon in a research report on Tuesday, March 26th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Haleon has an average rating of “Moderate Buy”.

Haleon Stock Performance

Shares of Haleon stock traded down $0.03 during midday trading on Monday, hitting $8.36. The company had a trading volume of 1,524,770 shares, compared to its average volume of 5,509,985. The stock has a market cap of $38.17 billion, a price-to-earnings ratio of 27.83, a PEG ratio of 2.23 and a beta of 0.26. The company has a quick ratio of 0.73, a current ratio of 1.04 and a debt-to-equity ratio of 0.53. The company has a fifty day simple moving average of $8.35 and a 200 day simple moving average of $8.33. Haleon plc has a 12-month low of $7.70 and a 12-month high of $8.96.

Haleon (NYSE:HLN) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.11 by $0.01. The firm had revenue of $3.70 billion during the quarter, compared to analyst estimates of $3.71 billion. Haleon had a net margin of 9.68% and a return on equity of 13.17%. As a group, analysts predict that Haleon plc will post 0.46 earnings per share for the current fiscal year.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.